2026-10-22 12:13:00 UTC#499893newconfirmednews
MBX stock news
MBX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire11 wire items
2026-10-12 11:29:00 UTC#446219newconfirmednews
Stifel raises MBX Biosciences price target to $84 from $70, maintains Buy rating
2026-10-02 13:15:00 UTC#405399newconfirmednews
Guggenheim maintains Buy rating on MBX Biosciences
2026-09-16 13:20:43 UTC#321000newconfirmednews
MBX Biosciences targets H2 2027 for canvuparatide Phase III enrollment; MBX 4291 data due in Q4
quartrimportance 0.40trust 0.60MBX Biosciences, Inc. +0.30canvuparatide +0.30MBX 4291 +0.30+1 entities
2026-08-27 12:43:01 UTC#229139newconfirmednews
MBX Biosciences initiates Phase 3 oPTimize trial for once-weekly canvuparatide in chronic hypoparathyroidism
2026-08-21 19:12:00 UTC#207177newconfirmednews
JPMorgan initiates coverage on MBX Biosciences with $88.00 price target
2026-08-13 11:57:54 UTC#171459newconfirmednews
MBX Biosciences Q3 2026 revenue rises 17% with margin expansion despite YTD China sales decline
2026-08-10 18:22:00 UTC#154300newconfirmednews
Truist Securities raises MBX Biosciences price target to $88 from $70
2026-08-06 20:23:25 UTC#140201newconfirmednews
MBX Biosciences average analyst price target raised to $83.40, implying 24% upside
2026-08-06 12:19:19 UTC#137150newconfirmednews
MBX Biosciences reports Q2 2026 GAAP EPS of -$0.78
2026-07-13 20:30:07 UTC#27651newconfirmednews
MBX Biosciences appoints Steve Hoerter as CEO and John Smither as CFO
seeking alphaimportance 0.30trust 0.80MBX Biosciences, Inc. +0.10Steve Hoerter +0.10John Smither +0.10